Share this video  

EBMT 2023 | A novel clinical trial endpoint for acute GvHD

James Ferrara, MD, DSc, Icahn School of Medicine at Mount Sinai, New York City, NY, comments on a novel early endpoint for acute graft-versus-host disease (GvHD) clinical trials combining the MAGIC algorithm probability (MAP) with the clinical response at week two, highlighting some of the issues associated with the currently used primary endpoint. Using this novel method, it is possible to distinguish three types of responses to treatment – complete, partial, and non-responses. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


US patent for serum biomarkers of GVHD

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter